
Retension Pharmaceutical
Developer of therapeutic drugs designed for patients with hypertension. The company's drug is a unique second-generation inhibitor that preferentially targets cardiovascular tissues, enabling patients...
Valuation
$50M
Latest known
Share Price
N/A
Total Raised
$22.4M
Last Round
N/A